
Ep. 380 - AZ-BMS rumors, Replimune, psychedelics
Episode 380
Rumors flew this weekend about a mega-merger of AstraZeneca and Bristol Myers — but would such a deal make sense? On the latest BioCentury This Week podcast, BioCentury’s analysts explain why they aren’t buying it. The team also discusses what lessons can be learned from the regulatory roller-coaster ride of Replimune’s RP1 vusolimogene oderparepvec and psychedelic therapies’ inflection point in treating depression. View full story: https://www.biocentury.com/article/660376 #BiotechMA #FDA #Psychedelics #Depression #OncolyticVirus 00:00 - Introduction 00:51 - AZ-BMS Rumors 08:07 - Replimune 20:46 - Psychedelics To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text
Publisher
BioCentury This Week
Published
August 4, 2026
Duration
32 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BioCentury
BioCentury This Week
@biocenturythisweek
#bmsrumors #replimune #psychedelics #lifesciences
